Abstract
Evidence-based policy has support in many areas of government and in public affairs more generally. In this paper we outline what evidence-based policy is, then we discuss its strengths and weaknesses. In particular, we argue that it faces a serious challenge to provide a plausible, over-arching account of evidence. We contrast evidence-based policy with evidence-based medicine, especially the role of evidence in assessing the effectiveness of medicines. The evidence required for policy decisions does not easily lend itself to randomized controlled trials (the “gold standard” in evidence-based medicine), nor, for that matter, being listed in a single all-purpose hierarchy.
Similar content being viewed by others
Notes
Head (2010) provides a good overview (with an extensive reference list). Davies et al. (2000a) is an earlier, comprehensive treatment of evidence-based policy. Like this literature, this paper focuses on the role and merits of specific forms of evidence for informing policy. An example of some of the broader discussions regarding the role of science and values in policy can be found in Douglas (2009).
EBM puts forward a number of hierarchies for different medical questions. We follow the literature on this topic and focus on the hierarchy provided for therapeutic decisions.
As Worrall (2002) notes, randomization does not ensure all possible confounding factors are equally balanced between the experimental groups. Confounding due to an unlucky consequence of random allocation is, however, a different type of error to the selection bias that can occur in observational studies.
Macintyre et al. (2001) provide examples from health policy where decisions that have ignored relevant empirical evidence have led to harm.
Incremental or mixed incremental-rational models of the policy process emphasize the incremental and disjointed nature of policy progress. While evidence and arguments about evidence play a more diffuse role in these models, evidence (broadly construed) remains central (Nutley and Webb 2000, p. 28).
Rawlins (2008) provides a good overview of some of the criticisms that have been raised from within medicine. For philosophical discussion, see Bluhm (2005), Cartwright (2007), Clarke et al. (2013, 2014), Grossman and Mackenzie (2005), La Caze (2008, 2009), Osimani (2014), and Worrall (2007). Cartwright (2009) and Roush (2009) discuss the use of randomized studies in policy and Montuschi (2009) discusses some of the broader problems of evidence in policy.
The importance of attending to the human elements of health are emphasised by proponents of narrative medicine. See Greenhalgh (2012) for a discussion on the importance of avoiding the reduction medical decision-making to “mathematical estimates of the change of benefit and the risk of harm derived from high-quality research” (Greenhalgh 2012, p. 94).
See also Cartwright and Hardie (2012).
See Steel (2004) for a discussion of social mechanisms.
See, for example, the recent policy decision by the Australian Government’s Biosecurity Australia to allow the importation of Cavendish bananas from the Philippines. The relevant import risk analysis report and policy decisions are available from the Australian Government’s Department of Agriculture Fisheries and Forestry website devoted to the matter: http://www.daff.gov.au/ba/ira/final-plant/banana-philippines.
Lindenmayer et al. (2012) provides examples of how carbon-trading policy can have unwanted downstream effects if the game-theoretic structure of the problem is not appreciated and Colyvan et al. (2011) discuss the importance of games against nature and adaptive management in conservation management decisions.
This might not be so different from some areas of medicine where organisms are known to have responded to continued treatment in ways not anticipated by initial randomized controlled trials. Think, for example, of the way antibiotic-resistant Staphylococci evolved in response to clinical interventions of sequential narrow spectrum antibiotics. While game theory is usually, and most obviously, applicable to sentient and rational agents, many non-sentient systems behave as though they were agents responding in the game in question. See Skyrms (2004) for more on the evolution of cooperation in non-sentient cases via evolutionary game theory. Examples such as the antibiotic-resistant Staphylococci suggest that faith in randomized-controlled trials, even in medicine, is problematic.
This advice is exemplified in Cartwright and Hardie (2012).
References
Angrist JD, Pischke JS (2010) The credibility revolution in empirical economics: how better research design is taking the con out of econometrics. J Econ Perspect 24(2):3–30
Bluhm R (2005) From hierarchy to network: a richer view of evidence for evidence-based medicine. Perspect Biol Med 48(4):535–547
Bohrnstedt GW, Stecher BM (eds) (2002) What we have learned about class size reduction. California Department of Education, Sacremento
Bornstein SR, Licinio J (2011) Improving the efficacy of translational medicine by optimally integrating health care, academia and industry. Nat Med 12:1567–1569
Cartwright N (2007) Are RCTs the gold standard? BioSocieties 2:11–20
Cartwright N (2009) Evidence-based policy: What’s to be done about relevance? Philos Stud 143(1):127–136
Cartwright N (2011) Predicting what will happen when we act. What counts for warrant? Prev Med 53(4–5):221–224
Cartwright N, Hardie J (2012) Evidence-based policy: a practical guide to doing it better. Oxford University Press, Oxford
Clarke B, Gillies D, Illari P, Russo F, Williamson J (2013) The evidence that evidence-based medicine omits. Prev Med 57:745–747
Clarke B, Gillies D, Illari P, Russo F, Williamson J (2014) Mechanisms and the evidence hierarchy. Topoi 33(2):339–360
Colyvan M, Justus J, Regan HM (2011) The conservation game. Biol Conserv 144(4):1246–1253
Davies HTO, Nutley SM, Smith PC (eds) (2000a) What works?: evidence based policy and practice in public services. Policy Press, Bristol
Davies HTO, Nutley SM, Tilley N (2000b) Debates on the role of experimentation. In: Davies HTO, Nutley SM, Smith PC (eds) What works?: evidence based policy and practice in public services. Policy Press, Bristol, pp 251–276
Douglas H (2009) Science, policy, and the value-free ideal. University of Pittsburgh Press, Pittsburgh
Druker B, Talpaz M, Resta D et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med 344(14):1031–1037
Evidence-Based Medicine Working Group (1992) Evidence-based medicine: a new approach to teaching the practice of medicine. J Am Med Assoc 268(17):2420–2425
Glass GV, Cahen LS, Smith ML, Filby NN (1982) School class size: research and policy. Sage Publications, Beverly Hills
Greenhalgh T (2012) Why do we always end up here? Evidence-based medicine’s conceptual cul-de-sacs and some off-road alternative routes. J Prim Health Care 4(2):92–97
Grossman J, Mackenzie FJ (2005) The randomized controlled trial: gold standard, or merely standard? Perspect Biol Med 48(4):516–534
Head BW (2008) Three lenses of evidence-based policy. Aust J Public Adm 67(1):1–11
Head BW (2010) Reconsidering evidence-based policy: key issues and challenges. Policy Soc 29(2):77–94
Hutton J, Smith PC (2000) Non-experimental quantitative methods. In: Davies HTO, Nutley SM, Smith PC (eds) What works?: evidence based policy and practice in public services. Policy Press, Bristol, pp 277–290
La Caze A (2008) Evidence based medicine can’t be…. Soc Epistemol 22(4):353–370
La Caze A (2009) Evidence based medicine must be …. J Philos Med 34:509–527
Leamer EE (1983) Let’s take the con out of econometrics. Am Econ Rev 73(1):31–43
Lindenmayer DB, Hulvey KB, Hobbs RJ, Colyvan M, Felton A, Possingham H, Steffen W, Wilson K, Youngentob K, Gibbons P (2012) Avoiding bio-perversity from carbon sequestration solutions. Conserv Lett 5(1):28–36
Lyseng-Williamson K, Jarvis B (2001) Imatinib. Drugs 61(12):1765–1774
Macintyre S, Chalmers I, Horton R, Smith R (2001) Using evidence to inform health policy: case study. Br Med J 322(7280):222–225
Montuschi E (2009) Questions of evidence in evidence-based policy. Axiomathes 19(4):425–439
Mosteller F (1995) The Tennessee study of class size in the early school grades. Future Child 5(2):113–127
Nutley SM, Webb J (2000) Evidence and the policy process. In: Davies HTO, Nutley SM, Smith PC (eds) What works?: evidence based policy and practice in public services. Policy Press, Bristol, pp 13–42
O’Brien S, Guilhot F, Larson R, Gathmann I, Baccarani M, Cervantes F et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 348(11):994–1004
Osimani B (2014) Hunting side effects and explaining them: Should we reverse evidence hierarchies upside down? Topoi 33(2):295–312
Rawlins MD (2008) De testimonio: on the use of evidence for decisions about the use of therapeutic interventions. Lancet 372(9656):2152–2161
Roush S (2009) Randomized controlled trials and the flow of information: comment on Cartwright. Philos Stud 143(1):137–145
Skyrms B (2004) The stag hunt and the evolution of the social contract. Cambridge University Press, Cambridge
Society for Prevention Research (2004) Standards of evidence: criteria for efficacy, effectiveness and dissemination. http://www.preventionresearch.org/advocacy/#SofE. Accessed 25 Nov 2013
Steel D (2004) Social mechanisms and causal inference. Philos Soc Sci 34(1):55–78
Walters CJ (1986) Adaptive management of renewable resources. MacMillan, New York
Worrall J (2002) What evidence in evidence-based medicine? Philos Sci 69:S316–S330
Worrall J (2007) Evidence in medicine and evidence-based medicine. Philos Compass 2(6):981–1022
Acknowledgments
An early version of this paper was presented at the 2009 Sydney-Tilburg Philosophy of Science Conference: ‘Evidence, Science, and Public Policy’ held at The University of Sydney, 26–28 March 2009. We’d like to thank the audience at that conference for fruitful discussion and several very helpful suggestions. We are also grateful to the referees of this journal for helpful suggestions.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
La Caze, A., Colyvan, M. A Challenge for Evidence-Based Policy. Axiomathes 27, 1–13 (2017). https://doi.org/10.1007/s10516-016-9291-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10516-016-9291-5